Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. develops gene-edited cell and gene therapies as a clinical-stage biotechnology company. Its recurring news centers on allogeneic CAR T immunotherapies in oncology, including off-the-shelf, gene-edited CAR T-cell product candidates, and on broader gene therapy research using its gene-editing platform and in-house manufacturing capabilities.
Company updates commonly cover clinical and partner-program developments for candidates such as lasme-cel, eti-cel and cema-cel; TALE-based and epigenetic editing research; financial results and business updates; collaborations and license arrangements; and monthly disclosures of share capital and voting rights for its Euronext Growth listing alongside its Nasdaq-listed ADS trading under CLLS.
Cellectis (CLLS) has reported its monthly share capital and voting rights information as of July 31, 2025. The company disclosed a total of 100,325,229 shares in its capital structure and 89,428,630 total voting rights. This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority for its listing on Euronext Growth.
Cellectis (NASDAQ:CLLS) reported Q2 2025 financial results and significant pipeline developments. The company's cash position stands at $230 million, providing runway into H2 2027. Key developments include the completion of end-of-Phase 1 meetings with FDA & EMA for lasme-cel (UCART22) in r/r B-ALL, with pivotal Phase 2 launch planned for H2 2025.
Financial highlights show consolidated revenues of $30.2 million for H1 2025, up from $16.0 million in H1 2024, primarily driven by a $20.0 million increase in AstraZeneca collaboration revenue. The company reported a net loss of $41.9 million ($0.42 per share) compared to $19.6 million ($0.24 per share) in the same period last year.
Pipeline progress includes ongoing Phase 1 study of eti-cel (UCART20x22) in r/r NHL with readout expected in late 2025, and advancement of three programs under the AstraZeneca partnership. A Servier arbitration decision is expected by December 15, 2025.
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing and cell therapies, will release its second quarter 2025 financial results on August 4, 2025 after U.S. market close.
The company will host an investor conference call and webcast on August 5, 2025 at 8:00 AM ET / 2:00 PM CET to discuss Q2 results and provide business updates. Investors can access the call through domestic (+1-800-343-5172) or international (+1-203-518-9856) dial-in numbers using Conference ID: CLLSQ2.
Cellectis (NASDAQ:CLLS) has released its monthly share capital and voting rights report as of June 30, 2025. The company reported a total of 100,325,229 shares in its capital structure and 89,428,630 voting rights.
This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority, as the company is listed on Euronext Growth.
Cellectis (NASDAQ:CLLS), a clinical-stage biotechnology company focused on gene-editing therapies, held its shareholders general meeting on June 26, 2025. With approximately 57% of voting rights exercised, shareholders approved 25 out of 26 resolutions.
The meeting resulted in significant board changes: Mr. André Muller, current CEO of Idorsia Pharmaceuticals, was appointed as a new board member, while Mr. Pierre Bastid resigned and Mr. Axel-Sven Malkomes' term expired. Muller brings extensive experience from his roles at Idorsia, Actelion Pharmaceuticals, and Pierre Fabre SA.
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing and cell and gene therapies, has announced its upcoming annual shareholders general meeting. The meeting is scheduled for June 26, 2025, at 2:30 p.m. CET and will be held at the Biopark auditorium in Paris, France. Shareholders can access detailed information about the meeting agenda and participation modalities through the company's website.
Cellectis (CLLS) has released its monthly share capital and voting rights report as of April 30, 2025. The company reported a total of 100,290,220 shares in its capital structure, with 89,075,490 total voting rights. This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority, as the company is listed on Euronext Growth.